Novartis unloads last piece of vaccines puzzle to CSL for $275M

After a lengthy strategic review and a handful of divestments, Novartis' ($NVS) slim-down effort is finally coming to a close. The company has sold off its flu vaccines business--the only piece of the vaccines unit it hung onto after a multibillion-dollar April transaction with GlaxoSmithKline ($GSK)--to Australia's CSL.

CSL will pay $275 million for the Swiss drugmaker's offerings, Novartis announced Sunday. That's not such a great deal for the Basel-based pharma, which will take an impairment charge of $1.1 billion on the deal. But not to fear, investors: The company expects to record a "substantial" one-time income gain from the GSK deal, which will "more than compensate" for the impairment charge.

While the CSL transaction may not offer a whole lot of financial benefit, it will help Novartis completely exit a troublesome business. The vaccine space has given Novartis fits since it formed the unit in 2006 with the $7.5 billion buyout of Chiron. The division foundered through several years as the company pinned hopes on the meningitis B vaccine Bexsero. But last year, the unit posted a $165 million operating loss.

Combined with the $7.1 billion vaccines sales to GSK, the CSL move will allow Novartis to double down on its core areas of focus, including pharmaceuticals, its Sandoz generics unit, and Alcon, its eye-care division. Along with vaccines, divestments have taken units for blood diagnostics and animal health out of the picture, and consumer health has joined up with Glaxo under a JV that the British drug giant will control.

As for CSL, combining the Novartis unit with its own subsidiary, bioCSL, will create the No. 2 player in the $4 billion global flu vaccine industry, it said in a statement. It'll have some big guns--like Sanofi ($SNY), AstraZeneca ($AZN) and Glaxo itself--to contend with.

- read Novartis' release
- read CSL's release

Special Reports: Top 5 vaccine makers by 2013 revenue - Novartis | The top 10 pharma companies by 2013 revenue - Novartis - GlaxoSmithKline

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.